In summary, the prevailing evidence argues in favor of investigating mutant TET2 allele dosage and TET2 protein expression as determinants of sensitivity to 5′-Aza in large prospective studies of AML and other hematological conditions characterized by TET2 loss of function. Here, TET2 is linked to acute myeloid leukemia.